Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat versus placebo in adolescents and adults with sickle cell disease
2024-511535-97-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Etavopivat with Placebo (2 arms). Primary endpoints: Hemoglobin response rate at Week 24 and Annualized vaso-occlusive crisis rate. Planned start Dec 2021; status: authorised.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-511535-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511535-97-00.